Episode Details

Atossa Therapeutics CEO Steven Quayjoined Steve Darling from Proactive to discuss the continued advancement of the company’s lead investigational therapy, (Z)-Endoxifen, and its potential applications across multiple breast cancer indications as well as certain rare diseases. The discussion highlighted the scientific foundation of the program, recent clinical data presentations, and key milestones expected in the months ahead. Quay explained that Atossa Therapeutics was founded with a clear mission focused on improving the prevention and treatment of breast cancer. Central to that strategy is the development of (Z)-Endoxifen, a therapy derived from decades of clinical experience and scientific understanding surrounding tamoxifen, one of the most widely prescribed treatments for hormone receptor-positive breast cancer. While tamoxifen has been a standard therapy for many years, its effectiveness depends on a patient’s ability to metabolize the drug into its active form, Endoxifen. Quay noted that this process can vary significantly between individuals due to genetic differences and metabolic factors. Atossa’s approach is to administer Endoxifen directly, potentially bypassing those limitations and providing more consistent therapeutic exposure across patients. According to Quay, clinical studies conducted to date have demonstrated encouraging signs of efficacy while maintaining what he described as a notably clean safety profile. The company believes the direct administration approach could offer meaningful advantages in both treatment and prevention settings. The CEO reviewed Atossa’s clinical progress, noting that the company has successfully completed multiple Phase 2 clinical trials evaluating Endoxifen in various breast cancer settings. These studies have generated data supporting the continued advancement of the program and helping to define potential pathways toward later-stage development. The findings presented at ASCO generated considerable interest, particularly data suggesting that Endoxifen may remain active in breast cancers that have developed mutations commonly associated with resistance to endocrine therapies. Resistance to hormonal treatments remains a significant challenge in breast cancer management, and the possibility of maintaining therapeutic activity in resistant tumors could represent an important clinical opportunity. Quay noted that feedback from oncologists, researchers, and industry participants at ASCO was highly encouraging, particularly regarding the potential implications of the resistance-related findings. Management believes these observations could help differentiate Endoxifen from existing treatment options and support future development strategies. Looking ahead, Atossa plans to consolidate results from multiple ongoing and completed clinical programs to build a comprehensive dataset supporting future regulatory discussions. The company intends to engage with regulatory authorities and potential pharmaceutical partners as it evaluates the most effective path toward Phase 3 clinical development and eventual commercialization. #proactiveinvestors #nasdaq #atos #BreastCancer #Endoxifen #Biotech #Oncology #ClinicalTrials #CancerResearch #ASCO #DrugDevelopment #HealthcareInnovation